4-(氨基甲基)-3-氯苯酚 | 771573-47-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(氨基甲基)-3-氯苯酚
• 英文名称: 4-(Aminomethyl)-3-chlorophenol
• CAS: 771573-47-8
• 化学式: C₇H₈ClNO
• 分子量: 157.6
• InChiKey: NSEFLFURUJFDTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3-{2-[(2R)-2-(tert-butyldimethylsilyloxy)-2-(4-hydroxy-3-methanesulfonylaminophenyl)ethylamino]-2-methylpropyl}phenyl)acetic acid 、 4-(氨基甲基)-3-氯苯酚 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 以74%的产率得到2-[3-(2-{[(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl]amino}-2-methylpropyl)phenyl]-N-(2-chloro-4-hydroxybenzyl)acetamide
  参考文献：
  名称：

  Inhalation by Design: Novel Ultra-Long-Acting β₂-Adrenoreceptor Agonists for Inhaled Once-Daily Treatment of Asthma and Chronic Obstructive Pulmonary Disease That Utilize a Sulfonamide Agonist Headgroup

  摘要：

  A novel series of potent and selective sulfonamide derived beta(2)-adrenoreceptor agonists are described that exhibit potential as inhaled ultra-long-acting bronchodilators for the treatment of asthma and chronic obstructive pulmonary disease. Analogues from this series mediate very long-lasting smooth muscle relaxation in guinea pig tracheal strips. The sulfonamide agonist headgroup confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state. Optimization of pharmacokinetic properties was achieved through targeted introduction of a phenolic moiety to support rapid phase II clearance, thereby minimizing systemic exposure following inhalation and reducing systemically mediated adverse events. Compound 38 (PF-610355) is identified as a clinical candidate from this series, with in vivo duration of action studies confirming, its potential for once-daily use in humans. Compound 38 is currently in advanced phase II clinical studies.

  DOI：

  10.1021/jm1005989
• 作为产物：
  描述：

  2-氯-4-羟基苯甲醛 在 盐酸羟胺 、 溶剂黄146 、 锌 作用下， 以 乙醇 、 水 为溶剂， 生成 4-(氨基甲基)-3-氯苯酚
  参考文献：
  名称：

  酚类噻吩并[2,3-d]嘧啶结合和激活雌激素受体 α 的结构决定因素

  摘要：

  使用合成、结构和计算方法来解决这样的难题：仅与其受体具有单个氢键的酚类非甾体雌激素1为何比形成复杂氢键网络的异构体2更有效。一系列取代酚的合成表明，pKa并不是雌激素活性的决定因素。第一性原理计算也未能解释1和2活性的差异。分子动力学表明，与2相比，1形成了更稳定的受体复合物，这可能解释了尽管与蛋白质形成的明显氢键较少，但其活性却增加了。

  DOI：

  10.1002/hlca.202300097

文献信息

• Formamide Derivatives For The Treatment of Diseases
  申请人：Brown Alan Daniel

  公开号：US20080207689A1

  公开（公告）日：2008-08-28

  The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

  本发明涉及式(1)化合物以及制备该化合物的中间体、含有该化合物的组合物的制备方法和用途。根据本发明的化合物在许多疾病、紊乱和状况中具有有用性，特别是在炎症、过敏和呼吸系统疾病、紊乱和状况方面。
• US7241810B2
  申请人：——

  公开号：US7241810B2

  公开（公告）日：2007-07-10
• US7547731B2
  申请人：——

  公开号：US7547731B2

  公开（公告）日：2009-06-16
• Inhalation by Design: Novel Ultra-Long-Acting β₂-Adrenoreceptor Agonists for Inhaled Once-Daily Treatment of Asthma and Chronic Obstructive Pulmonary Disease That Utilize a Sulfonamide Agonist Headgroup
  作者：Paul A. Glossop、Charlotte A. L. Lane、David A. Price、Mark E. Bunnage、Russell A. Lewthwaite、Kim James、Alan D. Brown、Michael Yeadon、Christelle Perros-Huguet、Michael A. Trevethick、Nicholas P. Clarke、Robert Webster、Rhys M. Jones、Jane L. Burrows、Neil Feeder、Stefan C. J. Taylor、Fiona J. Spence

  DOI：10.1021/jm1005989

  日期：2010.9.23

  A novel series of potent and selective sulfonamide derived beta(2)-adrenoreceptor agonists are described that exhibit potential as inhaled ultra-long-acting bronchodilators for the treatment of asthma and chronic obstructive pulmonary disease. Analogues from this series mediate very long-lasting smooth muscle relaxation in guinea pig tracheal strips. The sulfonamide agonist headgroup confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state. Optimization of pharmacokinetic properties was achieved through targeted introduction of a phenolic moiety to support rapid phase II clearance, thereby minimizing systemic exposure following inhalation and reducing systemically mediated adverse events. Compound 38 (PF-610355) is identified as a clinical candidate from this series, with in vivo duration of action studies confirming, its potential for once-daily use in humans. Compound 38 is currently in advanced phase II clinical studies.
• Structural Determinants of the Binding and Activation of Estrogen Receptor α by Phenolic Thieno[2,3‐<i>d</i>]pyrimidines
  作者：Vamshikrishna Reddy Sammeta、Brian M. Anderson、John D. Norris、Chad D. Torrice、Carstyn Joiner、Shubin Liu、Haoxi Li、Konstantin I. Popov、Sean W. Fanning、Donald P. McDonnell、Timothy M. Willson

  DOI：10.1002/hlca.202300097

  日期：2023.9

  Synthetic, structural, and computational approaches were used to solve the puzzle as to how a phenolic nonsteroidal estrogen 1 with only a single H-bond to its receptor was more potent than an isomer 2 which formed an intricate network of H-bonds. Synthesis of a series of substituted phenols revealed that pKa was not a determinant of estrogenic activity. First-principles calculation also failed to

  使用合成、结构和计算方法来解决这样的难题：仅与其受体具有单个氢键的酚类非甾体雌激素1为何比形成复杂氢键网络的异构体2更有效。一系列取代酚的合成表明，pKa并不是雌激素活性的决定因素。第一性原理计算也未能解释1和2活性的差异。分子动力学表明，与2相比，1形成了更稳定的受体复合物，这可能解释了尽管与蛋白质形成的明显氢键较少，但其活性却增加了。